Blood Test Instead of PET Scan: New Alzheimer Hope
At the world Alzheimer congress in London, new data shows a simple blood test can flag the disease much like a costly PET scan, even before the first symptoms appear.
- At the world Alzheimer congress in London (AAIC 2026, July 12-15), new data shows a simple blood test can flag the disease much like a costly PET scan.
- The test targets the biomarker P-tau217 and proves reliable even in people with no symptoms.
- A blood test would be far cheaper and more accessible than imaging, opening the door to earlier diagnosis.
- A group of GLP-1 drugs, the same ones used for diabetes, is also being studied to protect nerve cells and reduce brain inflammation.
Can early Alzheimer diagnosis fit into a single tube of blood? Data presented this week in London says we are closer to that than ever. As the world congress of the Alzheimer’s Association runs in the British capital, one of the largest pharmaceutical companies has released results that could change how the disease is detected in the first place.
Until now, reliably confirming Alzheimer pathology meant an expensive PET scan or an uncomfortable spinal tap. The message from the congress is simple: an ordinary blood test can do a similar job. For patients and families that is no small thing, it is the difference between waiting and acting in time.
How can an ordinary blood test see what it could not before?
The key is a molecule called P-tau217. It is one of the biomarkers that appears in the blood when the Alzheimer-related process begins in the brain. The data presented shows that measuring this biomarker flags the disease pathology much like a costly amyloid PET scan, the method long treated as the gold standard.
The most important part is that the test gives a signal even in people who have no symptoms yet. That means doctors could spot changes long before forgetfulness and confusion set in. An early picture of the disease creates room for earlier monitoring, family counseling and treatment planning.
Alongside these results, the company also shared long-term analyses of its drug Kisunla, also known as donanemab, on the balance of benefit and risk over an extended period of use. The expert message is cautious but encouraging: diagnostics and therapy are advancing side by side.
It is worth being clear here. A blood test is not a cure and does not stop the disease on its own. It is a tool that answers the question sooner. But in medicine time is often the most valuable resource, and a cheaper method means many more people can gain access to it.
Why cost may be the most important word here
Brain scans are not available to everyone. Machines are scarce, waiting lists are long, and the price is high even in wealthier health systems. As a result, many people reach a diagnosis only once symptoms are already pronounced.
A blood test changes that math. Drawing blood is a routine procedure that can be done at any local clinic. If the method is confirmed for wide use, early Alzheimer diagnosis becomes far cheaper and more accessible, not just a privilege of major centers.
It is also intriguing that a group of GLP-1 drugs, the same ones used for diabetes and weight loss, is being studied in parallel. Researchers are checking whether they can protect nerve cells and reduce inflammation in the brain. It is still early for conclusions, but the direction of research shows that diseases are increasingly viewed as connected rather than isolated.
For now the most concrete step is exactly this: a cheaper path to an early answer. And if a single blood test could reveal a loved one’s risk years in advance, would you want to know in time?
